QCDx News

December 8, 2021
UConn Today on the RareScope technology and CLINBREAC Clinical Trial
UConn Today Logo.jpg

The news source of the University of Connecticut highlighted the QCDx Microscope Technology and the presentation of latest CLINBREAC trial study results showing the RareScope power to identify hard to find circulating tumor cells (CTCs) in the blood of breast cancer patients.

Read Article

 
December 7, 2021
Exciting results on real-time and sensitive CTC characterization for treatment optimization presented by Dr. Susan Tannenbaum at the American Association for Cancer Research SABCS 2021 Meeting 
Tannenbaum_Susan_2016_JGelineau_9513Final_Portrait 517x400.jpg
"The promising technology has the unique potential to personalize and allow multiple concordant targeted therapies to be engaged that could have significant impact on patient outcomes" stated the Principal Investigator, Dr. Susan Tannenbaum.
 
The ongoing CLINBREAC clinical trial has accrued 21 early stage and metastatic patients from whom, blood samples are collected longitudinally and CTCs analyzed for type characterization of the disease and detection of biomarkers useful for treatment optimization.
Download SABCS 2021 poster
June 14, 2021
Dr. Tafas interview to CEOCFO magazine 
Lynn Fosse, CEOCFO Senior Editor interviewed Fyl Tafas and publishes in an article titled:
 
"The innovative QCDx technology may lead to truly optimized cancer treatment and have a significant impact on patient outcomes"
 
Read Tafas interview here
CEOCFO logo.jpg
April 19, 2021

Spencer Keilich PhD Lead Scientist, Fyl Tafas and the prototype RareScope at the QCDx product development facility in Farmington, CT.

HBJ April 6 2021.jpg
HBJ logo.jpg
March  25, 2021
QCDx is manufacturing the RareScope with Start
20210818_RareScope.jpg

The RareScope optical and opto-mechanical engineering concepts are implemented with full adherence to medical instrument quality and regulatory requirements to provide diagnostic safety and address post-market support during the RareScope life-cycle.

Start (Shelton, CT) is a company that innovates in medical instrument design, engineering, manufacturing and offers complete ISO 13485 certified product development. With this partnership, QCDx is securing that the RareScope instruments will meet the above requirements for commercial RareScope systems delivered in the translational research and diagnostic markets.

July 6, 2020
First patient is enrolled in the CLINBREAC Breast Cancer Study !

CLINBREAC is a single site, prospective, longitudinal trial for enrichment-free, over-time, CTC detection and characterization in breast cancer patients enrolled through the University of Connecticut, Carol and Ray Neag Comprehensive Cancer Center.

It aims to determine the potential clinical utility of the QCDx-br™ Liquid Biopsy Technology to optimize treatment options for breast cancer patients based on the RareScope ability to delineate marker expression on CTCs in real time that can lead to actionable change in treatment and even support novel combinations of treatments.

The CLINBREAC clinical trial protocol has been approved the University of Connecticut Institutional Review Board Principal Investigator is Professor Susan Tannenbaum MD, Chief, Division of Hematology/Oncology and Medical Director at Neag Comprehensive Cancer Center.

Please see Press Release announcing commencement fo the CLINBREAC Study

June 22,2020
QCDx presents poster at the AACR 2020 Meeting, on supporting work ahead of a clinical study for a novel breast cancer diagnostic.

At the Annual Meeting of the American Association for Cancer Research (AACR) on June 22, 2020, QCDx presented results from a study demonstrating the RareScope’s ability to detect rare cancer cells at frequencies expected in both early stage and metastatic disease in the blood of breast cancer patients. The results support the utilization of RareScope in the UConn IRB-approved clinical study for a novel breast cancer diagnostic. 

The abstract will be included in an online-only Proceedings supplement to the AACR journal Cancer Research following the AACR Virtual Annual Meeting II.

Read AACR 2020 Poster

January 21, 2020
QCDx Announces Sale of the RareScope to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health for Use in Clinical Research

QCDx is excited to grow its collaboration with the UConn Cancer Center and come to an agreement with Dr. Pramod K. Srivastava PhD MD, Director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, for the procurement of a RareScope instrument combined with RarePicker cell isolation.

"The RareScope can detect and isolate intact and live Circulating Tumor Cells from a blood sample of a cancer patient after analyzing every single nucleated cell,” said Dr. Srivastava. “We intend to use the ability of the RareScope to obtain a deep look into the genomes of cancer cells in patients undergoing standard-of-care and experimental treatments".

Read Full PressRelease

Photo from UConn Health faculty dir.jpg
 
November 19, 2019
UConn Institutional Review Board approves breast cancer diagnostic study

QCDx and the UConn Carole & Ray Neag Cancer Center with Dr. Susan Tannenbaum Principal Investigator, received approval by the UConn IRB of the prospective breast cancer diagnostic clinical study "Determination of the Potential Clinical Utility of the QCD:x-br™ Liquid Biopsy Technology to Optimize Treatment Options for Breast Cancer Patients". The study is scheduled to enroll 30 early stage and 30 metastatic patients.

For each patient, repeated blood samples will be collected during and after treatment. The goal is to assess correlations between CTCs of different phenotypes and the disease status. Detection will be done with the RareScope after fluorescence immunostaining for epithelial and mesenchymal CTC markers as well as markers related to hormone or targeted treatment. Available biopsied tissue will be analyzed by next generation sequencing offered commercially by Tempus Laboratories (Chicago, IL).

 

The study is co-sponsored by the CT Breast Health Initiative.

UConn Health Logo.JPG
November 13, 2019
Dr. Enrique Ballesteros MD joins QCDx as our Clinical Pathology Advisor

Dr., Ballesteros is joining QCDx to provide leading Medical Oncology expertise and guide development of clinical diagnostic assays utilizing the RareScope technology platform. 

Continuing the development of the RareScope platform, QCDx will assess clinical validity for the detection of CTCs in the blood of cancer patients. Dr. Tannenbaum will be the Principal Investigator of a study that will be conducted in collaboration with the UConn Carol & Ray Neag Comprehensive Cancer Center to explore clinical validity and potentially clinical utility of the RareScope in optimizing treatment options for breast cancer patients.

Dr. Tannenbaum will advise QCDx on other projects aiming to show the RareScope value for diagnostic applications in other cancers and for cancer research programs.

July 15, 2019
Dr. Susan Tannenbaum MD becomes QCDx Medical Oncology Advisor

Dr., Tannenabum is joining QCDx to provide leading Medical Oncology expertise and guide development of clinical diagnostic assays utilizing the RareScope technology platform. 

Continuing the development of the RareScope platform, QCDx will assess clinical validity for the detection of CTCs in the blood of cancer patients. Dr. Tannenbaum will be the Principal Investigator of a study that will be conducted in collaboration with the UConn Carol & Ray Neag Comprehensive Cancer Center to explore clinical validity and potentially clinical utility of the RareScope in optimizing treatment options for breast cancer patients.

Dr. Tannenbaum will advise QCDx on other projects aiming to show the RareScope value for diagnostic applications in other cancers and for cancer research programs.

May 5, 2019
Sir Walter Bodmer FRS, HonFRSE, FMedSci will be QCDx Mentor and Advisor for the development of RareScope applications

Sir Walter is a long-term Scientific Mentor for QCDx’s founders.

He has vast experience and decades of research in the fundamental genetics and biology of colorectal cancer (CRC) and their applications. As an experimental researcher in his substantial studies  of cancer related cellular pathways he was involved with the development of numerous antibodies against cancer related proteins and he will provide valuable guidance for the detection of rare cells in cancer related projects.

Sir Walter will also provide insights in other areas where the QCDx rare cell detection technology can be of value, such as in the prenatal detection of congenital anomalies or other congenital conditions.